CNBC's Jim Cramer has placed Palantir Technologies on his radar ahead of its quarterly report, expressing confidence in the data analytics firm's performance and highlighting the combative leadership style of CEO Alex Karp.
President Trump's nomination of Kevin Warsh for Federal Reserve Chair places the former governor in a precarious position, tasked with navigating the President's demands for lower rates while maintaining the central bank's credibility.
HP Inc. announced an immediate leadership transition on Tuesday, appointing board member Bruce Broussard as interim CEO after Enrique Lores stepped down to pursue a new opportunity.
NVIDIA's previously discussed multi-billion dollar investment in OpenAI has stalled, with CEO Jensen Huang clarifying the figure was never a binding commitment. The development redirects investor attention to the chipmaker's capital discipline and diversified partnerships amid soaring AI infrastructure demand.
PayPal Holdings Inc. announced on Tuesday the appointment of Enrique Lores as its new President and Chief Executive Officer, with the leadership transition set to take effect on March 1.
A new JPMorgan survey reveals a stark divergence: while 89% of the world's wealthiest family offices hold no crypto, 65% are prioritizing AI investments. Yet, beneath the headline trend, a parallel wave of structured crypto allocation is building among institutional players.
A California entrepreneur's rapid rise and financial collapse highlights a critical, often misunderstood IRS rule: some debts, like unpaid payroll taxes, follow you forever.
Despite a challenging environment for software stocks, analysts from DA Davidson and Bank of America reaffirm their confidence in Snowflake's long-term growth story, citing its unique positioning in the AI-driven data landscape.
Axsome Therapeutics (AXSM) reported preliminary 2025 revenue of $638.5 million, a 66% year-over-year surge that exceeded analyst forecasts, driven by the blockbuster performance of its depression treatment AUVELITY.
Mirum Pharmaceuticals charts a distinct course in the rare disease biotech landscape, leveraging strategic acquisitions to build a broad, sustainable pipeline while navigating a complex regulatory environment.
Choice Hotels' extended-stay brand Everhome Suites continues its aggressive growth strategy, opening new properties in Texas, Kentucky, and New Jersey to cater to both corporate and leisure travelers seeking apartment-style accommodations.
President Trump's nomination of Kevin Warsh to lead the Federal Reserve has drawn mixed reactions from markets and analysts, raising questions about the central bank's future independence and the appointee's consistent alignment with the sitting president's economic preferences.
In a new op-ed, Palantir's Shyam Sankar challenges prevailing narratives on AI-driven unemployment, asserting that historical parallels and frontline worker experiences reveal a net positive impact on job creation and productivity.
Greenland's Foreign Minister Vivian Motzfeldt expressed cautious optimism about reaching a diplomatic understanding with the United States that respects the island's core interests, during a key Arctic policy conference in Norway.
Hundreds of unionized hospitality workers in Minneapolis are staying off the streets, unconvinced by federal assurances of a softer immigration enforcement approach. The ongoing fear is crippling local businesses and deepening community distrust.
A wave of regulatory action is sweeping across continents as governments, citing mounting mental health and safety concerns, impose new age restrictions and bans on social media access for minors. Australia leads with a landmark under-16 ban, while European nations and others follow with similar proposals.
As borrowing costs surge and U.S. bank lending tightens, Oracle is reportedly considering cutting tens of thousands of jobs to free up cash for its capital-intensive AI data center build-out, with potential ripple effects across the cloud industry.
Merck & Co. projected 2026 revenue below Wall Street expectations, citing a steeper-than-anticipated impact from patent expirations on key drugs like Januvia. The forecast overshadowed a strong Q4 performance driven by its blockbuster cancer therapy, Keytruda.
Building on initial success in essential tremor trials, the expanded partnership leverages real-world data to streamline epilepsy studies, aiming to cut development timelines for central nervous system disorders.
A push for a federal cap on credit card interest rates, championed by former President Trump and aligned with a Sanders bill, faces scrutiny from economists who warn it could backfire, restricting credit for the very borrowers it aims to protect.
